Apixaban/rivaroxaban

In a prospective, non-interventional multi-centric Dresden NOAC, cohort study of 26 patients, 11 patients (7 men and 4 women) aged 48−79 years were described, who developed skin bleeding, fatal traumatic intracranial haemorrhage, macro-haematuria, gastrointestinal (GI) bleeding, haematemesis, hypermenorrhoea, haemoptysis, rectal bleeding or haemorrhoid bleeding following off label administration of rivaroxaban for acute or chronic splanchnic vein thrombosis (SVT). One of these patients was also receiving vitamin K antagonist [specific drug not stated]. Additionally, two of these patients also developed GI bleeding during apixaban treatment [not all dosages and outcomes stated].

Patient 2: The 51-year-old woman started receiving rivaroxaban for SVT. On day 569, she developed...